TEKTURNA HCT
LOE Approachingaliskiren hemifumarate; hydrochlorothiazide
NDAORALTABLET
Approved
Jan 2008
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
3/8 — Basic
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEKTURNA HCT is a fixed-dose combination tablet containing aliskiren hemifumarate (a direct renin inhibitor) and hydrochlorothiazide (a thiazide diuretic) for oral administration. It is indicated for hypertension management in patients who require dual antihypertensive therapy. The combination works synergistically to lower blood pressure through renin-angiotensin system inhibition and diuretic mechanisms.
$0.388MPart D
LOE ApproachingDeclining
2.2 years to LOEMinimal commercial momentum with 640 Part D claims and declining spend; brand team likely focused on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.